CTA
EW icon

Chesley Taft & Associates’s Edwards Lifesciences EW Stock Holding History

Chesley Taft & Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.55M Buy
28,154
+3
+0% +$251 0.1% 143
2026
Q1 		$2.25M Hold
28,151
– – 0.09% 147
2025
Q4 		$2.4M Buy
28,151
+1,446
+5% +$119K 0.09% 142
2025
Q3 		$2.08M Sell
26,705
-136
-0.5% -$10.6K 0.09% 153
2025
Q2 		$2.1M Sell
26,841
-285
-1% -$21.3K 0.09% 144
2025
Q1 		$1.97M Sell
27,126
-1,708
-6% -$122K 0.1% 144
2024
Q4 		$2.13M Sell
28,834
-420
-1% -$29.4K 0.1% 137
2024
Q3 		$1.93M Sell
29,254
-2,402
-8% -$175K 0.09% 147
2024
Q2 		$2.92M Buy
31,656
+1,105
+4% +$97.9K 0.15% 109
2024
Q1 		$2.92M Buy
30,551
+184
+0.6% +$15.5K 0.15% 113
2023
Q4 		$2.32M Sell
30,367
-80
-0.3% -$5.57K 0.13% 127
2023
Q3 		$2.11M Sell
30,447
-1,140
-4% -$91.6K 0.14% 124
2023
Q2 		$2.98M Sell
31,587
-630
-2% -$54.8K 0.18% 107
2023
Q1 		$2.67M Buy
32,217
+210
+0.7% +$16.5K 0.17% 120
2022
Q4 		$2.39M Sell
32,007
-55
-0.2% -$4.24K 0.16% 123
2022
Q3 		$2.65M Sell
32,062
-120
-0.4% -$11.5K 0.2% 109
2022
Q2 		$3.06M Sell
32,182
-6,305
-16% -$653K 0.21% 107
2022
Q1 		$4.65M Sell
38,487
-2,972
-7% -$333K 0.27% 82
2021
Q4 		$5.37M Sell
41,459
-1,475
-3% -$172K 0.28% 84
2021
Q3 		$4.86M Sell
42,934
-2,025
-5% -$231K 0.28% 83
2021
Q2 		$4.66M Sell
44,959
-610
-1% -$57.5K 0.27% 85
2021
Q1 		$3.91M Sell
45,569
-890
-2% -$75.2K 0.23% 90
2020
Q4 		$4.24M Buy
46,459
+625
+1% +$51.8K 0.27% 81
2020
Q3 		$3.66M Sell
45,834
-1,920
-4% -$150K 0.26% 85
2020
Q2 		$3.3M Sell
47,754
-570
-1% -$40.5K 0.25% 87
2020
Q1 		$3.04M Sell
48,324
-327
-0.7% -$23.6K 0.28% 80
2019
Q4 		$3.78M Sell
48,651
-855
-2% -$66.8K 0.27% 79
2019
Q3 		$3.63M Sell
49,506
-855
-2% -$60.1K 0.28% 79
2019
Q2 		$3.1M Sell
50,361
-240
-0.5% -$14.5K 0.24% 85
2019
Q1 		$3.23M Sell
50,601
-16,950
-25% -$967K 0.27% 78
2018
Q4 		$3.45M Sell
67,551
-435
-0.6% -$22K 0.33% 76
2018
Q3 		$3.94M Buy
67,986
+2,700
+4% +$132K 0.31% 77
2018
Q2 		$3.17M Sell
65,286
-999
-2% -$46.6K 0.27% 86
2018
Q1 		$3.08M Buy
66,285
+141
+0.2% +$6.12K 0.27% 87
2017
Q4 		$2.48M Sell
66,144
-32,448
-33% -$1.19M 0.21% 103
2017
Q3 		$3.59M Buy
98,592
+717
+0.7% +$27.3K 0.31% 83
2017
Q2 		$3.86M Buy
97,875
+20,115
+26% +$734K 0.35% 81
2017
Q1 		$2.44M Buy
77,760
+4,290
+6% +$134K 0.23% 97
2016
Q4 		$2.29M Buy
73,470
+44,400
+153% +$1.44M 0.23% 94
2016
Q3 		$1.17M Buy
+29,070
New +$1.09M 0.12% 140
2014
Q1 		– Sell
-117,840
Closed -$1.29M – 258
2013
Q4 		$1.29M Sell
117,840
-16,812
-12% -$190K 0.13% 139
2013
Q3 		$1.56M Buy
134,652
+150
+0.1% +$1.75K 0.17% 126
2013
Q2 		$1.51M Buy
+134,502
New +$1.59M 0.17% 121

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Chesley Taft & Associates's EW Position: Q2 2026 in Review

Chesley Taft & Associates increased its Edwards Lifesciences (EW) stake by 0.01% in Q2 2026, buying an estimated $251 and bringing the position to 28,154 shares worth $2.55M. The position accounts for 0.1% of the portfolio, ranked #143.

Chesley Taft & Associates first reported a position in EW in Q2 2013 and has held it in 43 quarters since. The position peaked at $5.37M in Q4 2021. 372 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Chesley Taft & Associates held 28,154 shares of Edwards Lifesciences worth $2.55M as of Q2 2026.
  • Chesley Taft & Associates bought 3 Edwards Lifesciences shares in Q2 2026, an estimated $251.
  • Edwards Lifesciences made up 0.1% of Chesley Taft & Associates's portfolio in Q2 2026, its #143 holding.
  • Chesley Taft & Associates first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 43 quarters since.
  • Chesley Taft & Associates's Edwards Lifesciences position peaked at $5.37M in Q4 2021.
  • 372 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Chesley Taft & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.